These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 21982686)
41. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Hershman DL; Weimer LH; Wang A; Kranwinkel G; Brafman L; Fuentes D; Awad D; Crew KD Breast Cancer Res Treat; 2011 Feb; 125(3):767-74. PubMed ID: 21128110 [TBL] [Abstract][Full Text] [Related]
50. Severe vincristine neurotoxicity in a patient with Charcot-Marie-Tooth disease. Dickerhoff R; Lindner W; Scheiber W Pediatr Hematol Oncol; 1988; 5(1):61-4. PubMed ID: 3152952 [No Abstract] [Full Text] [Related]
51. Molecular mechanisms for Charcot-Marie-Tooth disease and related demyelinating peripheral neuropathies. Warner LE; Reiter LT; Murakami T; Lupski JR Cold Spring Harb Symp Quant Biol; 1996; 61():659-71. PubMed ID: 9246492 [No Abstract] [Full Text] [Related]
52. Leber's optic neuropathy and Charcot-Marie-Tooth disease. Report of a case. McCluskey DJ; O'Connor PS; Sheehy JT J Clin Neuroophthalmol; 1986 Jun; 6(2):76-81. PubMed ID: 2942573 [TBL] [Abstract][Full Text] [Related]
53. Neurotoxicity as a possible manifestation of paclitaxel hypersensitivity reactions. McCauley DL; Calzone K; Wicha M J Clin Oncol; 1994 May; 12(5):1102-3. PubMed ID: 7909329 [No Abstract] [Full Text] [Related]
54. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Argyriou AA; Antonacopoulou AG; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP Oncology; 2009; 77(3-4):254-6. PubMed ID: 19738391 [TBL] [Abstract][Full Text] [Related]
55. Oxaliplatin (Eloxatin) for advanced colon cancer. Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541 [No Abstract] [Full Text] [Related]
56. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. Ichikawa M; Suzuki D; Inamoto J; Ohshima J; Cho Y; Saitoh S; Kaneda M; Iguchi A; Ariga T J Pediatr Hematol Oncol; 2012 Apr; 34(3):239-41. PubMed ID: 22246157 [TBL] [Abstract][Full Text] [Related]
57. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738 [TBL] [Abstract][Full Text] [Related]
58. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. Nishikawa T; Kawakami K; Kumamoto T; Tonooka S; Abe A; Hayasaka K; Okamoto Y; Kawano Y J Pediatr Hematol Oncol; 2008 Jul; 30(7):519-21. PubMed ID: 18797198 [TBL] [Abstract][Full Text] [Related]
59. Severe anaphylactic reactions to oxaliplatin. Tournigand C; Maindrault-Goebel F; Louvet C; de Gramont A; Krulik M Eur J Cancer; 1998 Jul; 34(8):1297-8. PubMed ID: 9849497 [No Abstract] [Full Text] [Related]
60. The case of the tingling toes. Eisenberg S ONS Connect; 2011 Sep; 26(9):17. PubMed ID: 21954796 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]